Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.
Anticancer Res. 2013 Aug;33(8):3355-8.
BACKGROUND/AIM: The liver is the most frequent site of metastasis of pancreatic neuroendocrine tumors (PNETs). Moreover, hepatic metastasis is a strong prognostic factor for patients with advanced PNETs and is often difficult to treat and cure.
We employed our recently developed new transcatheter arterial chemoembolization technique using a fine-powder formulation of cisplatin mixed with degradable starch microspheres (DSM) for the treatment of unresectable hepatic metastases from PNET in five consecutive patients.
A total of 24 sessions of TACE was performed. The responses were complete response in one, partial response in three, and stable disease in one patient. All patients were alive at the time of analysis with a median survival of 36 (3-70) months after the initial treatment of TACE. There were no severe toxicities or adverse effects.
This new treatment induced a significant effect on hepatic metastases of PNET. The response rate was very high, which has not been achieved even by recent new agents. Our findings may warrant further prospective studies of this therapy.
背景/目的：肝脏是胰腺神经内分泌肿瘤（PNET）转移最常见的部位。此外，肝转移是晚期 PNET 患者的一个强烈预后因素，且往往难以治疗和治愈。
我们使用最近开发的新经导管动脉化疗栓塞技术，用顺铂细粉制剂与可降解淀粉微球（DSM）混合，治疗五例连续的不可切除的 PNET 肝转移患者。
共进行了 24 次 TACE。反应完全缓解 1 例，部分缓解 3 例，疾病稳定 1 例。在分析时，所有患者均存活，自 TACE 初始治疗后中位生存时间为 36（3-70）个月。没有严重的毒性或不良反应。
这种新的治疗方法对 PNET 的肝转移有显著疗效。反应率非常高，即使是最近的新药物也未能达到这一水平。我们的发现可能需要对这种治疗方法进行进一步的前瞻性研究。
